Emir Zonic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Emir Zonic has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anett Kaune
Centogene GmbH, Rostock, Germany
1 shared publication - Christian Beetz
Centogene GmbH, Rostock, Germany
1 shared publication - Daniel Schulze
Charité - Universitätsmedizin Berlin, Institute of Biometry and Clinical Epidemiology, Germany
1 shared publication - Deepa Saravanakumar
Centogene GmbH, Rostock, Germany
1 shared publication - Jorge Pinto Basto
Centogene GmbH, Rostock, Germany
1 shared publication Omid Paknia
Centogene GmbH, Rostock, Germany
1 shared publication
Latest Publications
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (4) , e200271
A Retrospective Cohort Study of the GLA c.937G > T, p.Asp313Tyr Variant With No Evidence of an Association With Fabry Disease
Fabry disease (FD) is a multisystemic disorder caused by pathogenic variants in the α-galactosidase (GLA) gene. There is ongoing debate on the disease-causing properties of the GLA variant NM_000169.3: c.937G > T, p.Asp313Tyr (D313Y). Like many others, we recently reclassified this variant from “variant of uncertain significance” to “benign.” By leveraging Centogene's Biodatabank, we reassessed our classification and analyzed all samples (n = 38,242) molecularly tested for FD from Germany between 2015 and 2020 for GLA genotypes, clinical presentations, and biochemical phenotypes. The allele frequency of GLA variant p.Asp313Tyr in our cohort was increased compared with gnomAD v4.1.0 data for European (non-Finnish) population resulting in an odds ratio of 2.13 (95% CI 1.94–2.33; p < 0.0001). Compared with individuals without any GLA variant, there was no specific clinical nor biochemical phenotype in this group, supporting a diagnosis of FD. GLA variant p.Asp313Tyr is to be classified as a benign variant and does not cause FD. Because an enrichment of patients with this variant in specific high-risk populations has been seen in this cohort and by other groups, properly designed case-control studies are needed to clarify a potential role of p.Asp313Tyr as risk factor or modifier of a FD-independent dysfunction.
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (4) , e200271
Open AccessA Retrospective Cohort Study of the GLA c.937G > T, p.Asp313Tyr Variant With No Evidence of an Association With Fabry Disease
Fabry disease (FD) is a multisystemic disorder caused by pathogenic variants in the α-galactosidase (GLA) gene. There is ongoing debate on the disease-causing properties of the GLA variant NM_000169.3: c.937G > T, p.Asp313Tyr (D313Y). Like many others, we recently reclassified this variant from “variant of uncertain significance” to “benign.” By leveraging Centogene's Biodatabank, we reassessed our classification and analyzed all samples (n = 38,242) molecularly tested for FD from Germany between 2015 and 2020 for GLA genotypes, clinical presentations, and biochemical phenotypes. The allele frequency of GLA variant p.Asp313Tyr in our cohort was increased compared with gnomAD v4.1.0 data for European (non-Finnish) population resulting in an odds ratio of 2.13 (95% CI 1.94–2.33; p < 0.0001). Compared with individuals without any GLA variant, there was no specific clinical nor biochemical phenotype in this group, supporting a diagnosis of FD. GLA variant p.Asp313Tyr is to be classified as a benign variant and does not cause FD. Because an enrichment of patients with this variant in specific high-risk populations has been seen in this cohort and by other groups, properly designed case-control studies are needed to clarify a potential role of p.Asp313Tyr as risk factor or modifier of a FD-independent dysfunction.